biote Corp. (BTMD) Form 10-Q — Aug 7, 2026
biote Corp. reported Q2 2026 revenue of $44.2 million, down 9.5% year over year, and swung to a net loss of $7.4 million ($0.23 per share) from net income of $3.9 million a year earlier, with Adjusted EBITDA falling to $5.6 million from $15.2 million. The January 2026 voluntary recall of hormone pellets due to potential metal particulate matter cut estimated pellet procedure revenue by $3.3 million in the quarter and drove $0.8 million of recall costs, with additional costs expected as the company rebuilds supply through a second manufacturing shift at its Asteria Health 503B facility.
Key figures
- Revenue
- 44232000
- Revenue Yoy
- -9.5%
- Total Assets
- 101699000
- Cash Position
- 11168000
- Shares Outstanding
- 28677589
- Q2 Share Buyback
- $4.8 million for 2,436,177 Class A shares at $2.05 average
- Six Month Revenue
- 89167000
- Adjusted EBITDAQ2
- 5561000
- Six Month Revenue Yoy
- -8.9%
- Recall Costs Six Months
- 2200000
- Recall Revenue Impact Q2
- 3300000
- Revolving Loan Capacity
- 50000000
- Six Month Adjusted EBITDA
- 14286000
- Legal Settlement Charge Q2
- 5100000
- Loss On Debt Extinguishment
- 648000
- Adjusted EBITDAQ2 Prior Year
- 15174000
- Operating Cash Flow Six Months
- 2726000
- Term Loan Refinancing Proceeds
- 125000000
- Recall Revenue Impact Six Months
- 5000000
- Remaining Buyback Authorization
- 5200000
Price after filing
Close on the filing date to close N calendar days later (from $1.48). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.